Role of MDSCs and Cancer Stem Cells and Their Cross Talks in NSCLC

Launched by UNIVERSITY HOSPITAL, BORDEAUX · Aug 28, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how certain cells in the immune system, known as Myeloid-Derived Suppressor Cells (MDSCs), affect lung cancer. Researchers want to understand how these cells might help cancer grow and spread, even though they normally help protect the body from diseases. They will do this by looking at samples from patients who have had surgery for lung cancer. The goal is to learn more about how these immune cells can suppress the body’s natural defenses against cancer and contribute to the disease's progression.

To be eligible for this trial, participants must be adults aged 65 to 74 who have had lung cancer treated with surgery only. Unfortunately, those who have received chemotherapy, radiation, or immunotherapy before surgery, or who have had another type of cancer in the past two years, cannot participate. Those who join the trial will help researchers gain valuable insights that could lead to better treatments in the future. The study is not yet recruiting participants, so there will be more information available soon.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • consecutive patients
• • lung carcinoma surgically treated by surgery only
• Exclusion Criteria:
• • patient receiving chemotherapy, radiotherapy or immunotherapy in the neoadjuvant setting (all objectives)
• • patient with concomitant or previous cancer (in the 2 years)